enrasentan has been researched along with Cardiac Remodeling, Ventricular in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barlow, MM; Cleland, JG; Dargie, HJ; Groenning, BA; Grothues, F; Pennell, DJ; Prasad, SK; Smith, GC | 1 |
| Aiyar, N; Anderson, KM; Barone, FC; Coatney, RW; Nelson, AH; Ohlstein, EH; Olzinski, AR; Willette, RN; Woods, T | 1 |
1 trial(s) available for enrasentan and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Carboxylic Acids; Disease Progression; Enalapril; Female; Heart Failure; Humans; Indans; Magnetic Resonance Angiography; Male; Middle Aged; Neurotransmitter Agents; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Remodeling | 2006 |
1 other study(ies) available for enrasentan and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Carboxylic Acids; Endothelin Receptor Antagonists; Heart Rate; Hypertension; Hypertrophy, Left Ventricular; Indans; Male; Myocardium; Protein Precursors; Rats; Rats, Inbred SHR; Survival Rate; Ventricular Remodeling | 2001 |